ERBB2 and non-small cell lung carcinoma: In the latest years, several tyrosine kinase inhibitors have been developed to target different novel driver gene alterations other than EGFR, ALK, ROS-1 and BRAF, including RET, MET and ERBB2, and some of them have already received approval by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of advanced NSCLC.